Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Actavis Inc       US9426831031

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Watson Pharmaceuticals, Inc. : Watson to Present at the Bank of America Merrill Lynch 2012 Health Care Conference

05/04/2012 | 04:05pm US/Eastern

PARSIPPANY, N.J., May 4, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty global pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the Bank of America Merrill Lynch 2012 Healthcare Conference on Wednesday, May 16, 2012 at 10:00 AM Pacific Time at the Encore at the Wynn in Las Vegas, Nevada. The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Website at http://ir.watson.com. The webcast can also be accessed at the following URL: http://www.veracast.com/webcasts/baml/healthcare2012/id16635640.cfm

An archived version will be available approximately one hour after the live presentation ends and can be accessed at the same locations for 90 days.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. The Company is also developing biosimilar products in Women's Health and Oncology. Additionally, Watson distributes generic and branded pharmaceuticals through its Anda, Inc. distribution business. Watson has operations in many of the worlds established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

    CONTACTS:                         Investors:
                                      Lisa DeFrancesco
                                      (862) 261-7152

                                      Media:
                                      Charlie Mayr
                                      (862) 261-8030

(Photo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

SOURCE Watson Pharmaceuticals, Inc.

React to this article
Latest news on ACTAVIS INC
1d ago ACTAVIS : XYDALBA(TM) (dalbavancin) Receives CHMP Positive Opinion for the Treat..
1d ago ACTAVIS : to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
4d agoDJU.S. HOT STOCKS : Hot Stocks to Watch
4d agoDJActavis CEO to Remain After Allergan Merger
5d agoDJBrent Saunders faces challenge of running combined Actavis-Allergan
12/10 ACTAVIS : Launches Generic Version of Celebrex®
12/09DJMerck Reaffirms Commitment to Cubist Deal Despite Patent Ruling -- Update
12/09 Exclusive - Valeant to drop deal-making in near term to cut debt, boost stock
12/09DJMerck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 6th Update
12/09DJMerck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 5th Update
Dynamic quotes  
ON
| OFF